Medtronic/$MDT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Medtronic
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Ticker
$MDT
Sector
Primary listing
NYSE
Employees
95,000
Headquarters
Galway, Ireland
Website
Medtronic Metrics
BasicAdvanced
$120B
25.87
$3.62
0.79
$2.82
3.03%
Price and volume
Market cap
$120B
Beta
0.79
52-week high
$99.37
52-week low
$79.29
Average daily volume
7.1M
Dividend rate
$2.82
Financial strength
Current ratio
2.014
Quick ratio
1.248
Long term debt to equity
54.389
Total debt to equity
61.393
Dividend payout ratio (TTM)
77.27%
Interest coverage (TTM)
8.95%
Profitability
EBITDA (TTM)
9,446
Gross margin (TTM)
65.37%
Net profit margin (TTM)
13.63%
Operating margin (TTM)
19.31%
Effective tax rate (TTM)
17.15%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
4.57%
Return on equity (TTM)
9.74%
Valuation
Price to earnings (TTM)
25.87
Price to revenue (TTM)
3.513
Price to book
2.5
Price to tangible book (TTM)
-22.32
Price to free cash flow (TTM)
22.657
Free cash flow yield (TTM)
4.41%
Free cash flow per share (TTM)
4.134
Dividend yield (TTM)
3.01%
Forward dividend yield
3.03%
Growth
Revenue change (TTM)
4.98%
Earnings per share change (TTM)
21.95%
3-year revenue growth (CAGR)
3.25%
10-year revenue growth (CAGR)
3.99%
3-year earnings per share growth (CAGR)
-2.24%
10-year earnings per share growth (CAGR)
5.35%
3-year dividend per share growth (CAGR)
3.02%
10-year dividend per share growth (CAGR)
8.05%
What the Analysts think about Medtronic
Analyst ratings (Buy, Hold, Sell) for Medtronic stock.
Bulls say / Bears say
Medtronic raised its fiscal 2026 profit forecast to $5.60–$5.66 per share, citing a lower-than-expected tariff impact of approximately $185 million, demonstrating operational resilience amid geopolitical uncertainties (Reuters).
The company reported Q1 FY26 revenue of $8.6 billion, up 8.4% as reported and 4.8% organically—its 11th consecutive quarter of mid-single-digit organic growth—driven by strength across its cardiovascular, neuroscience, surgical, and diabetes businesses (Ainvest).
Key innovation milestones—including CE Mark approval for its LigaSure RAS vessel-sealing technology on the Hugo robotic system and a proposed CMS National Coverage Determination for Symplicity Spyral hypertension therapy—signal Medtronic’s expanding pipeline of high-growth products (Ainvest).
The FDA classified its recall of Pipeline Vantage Embolization devices as the most serious (Class I), following reports of four patient deaths and thirteen injuries, highlighting significant liability and reputational risks (Reuters).
Newly imposed U.S. tariffs could raise Medtronic’s cost of goods sold by up to $950 million in fiscal 2026, and even after mitigating $600 million through supply-chain adjustments, the remaining headwind may compress margins (Barron’s).
Medtronic plans to spin off its $2.8 billion Diabetes division into a standalone public company within 18 months, introducing near-term execution risk and potentially removing a high-growth segment from its core portfolio (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Medtronic Financial Performance
Revenues and expenses
Medtronic Earnings Performance
Company profitability
Medtronic News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Medtronic stock?
Medtronic (MDT) has a market cap of $120B as of October 26, 2025.
What is the P/E ratio for Medtronic stock?
The price to earnings (P/E) ratio for Medtronic (MDT) stock is 25.87 as of October 26, 2025.
Does Medtronic stock pay dividends?
Yes, the Medtronic (MDT) stock pays dividends to shareholders. As of October 26, 2025, the dividend rate is $2.82 and the yield is 3.03%. Medtronic has a payout ratio of 77.27% on a trailing twelve-month basis.
When is the next Medtronic dividend payment date?
The next Medtronic (MDT) dividend payment date is unconfirmed.
What is the beta indicator for Medtronic?
Medtronic (MDT) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.